US Patent

US10174041 — Methods and compositions for inhibiting the interaction of menin with MLL proteins

Method of Use · Assigned to University of Michigan System · Expires 2036-03-16 · 10y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods and compositions for inhibiting the interaction of menin with certain proteins to treat various diseases.

USPTO Abstract

The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.

Drugs covered by this patent

Komzifti (ZIFTOMENIB) · Kura

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4350`	—	Komzifti

Patent Metadata

Patent number: US10174041
Jurisdiction: US
Classification: Method of Use
Expires: 2036-03-16
Drug substance claim: No
Drug product claim: No
Assignee: University of Michigan System
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.